Who founded Mulberry Biotherapeutics?

Mulberry Biotherapeutics was founded by Gary Brenner, John Mekalanos in 2020.

How much funding has Mulberry Biotherapeutics raised?

Mulberry Biotherapeutics has disclosed $2.1M raised across 1 round.

Where is Mulberry Biotherapeutics headquartered?

Mulberry Biotherapeutics is headquartered in Wellesley, US.

Mulberry Biotherapeutics

Wellesley, US · Founded 2020 · Delaware corporation

Find your way into Mulberry Biotherapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Mulberry Biotherapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.

Biotech Healthtech

Founders & leadership

Mulberry Biotherapeutics was founded in 2020 by Gary Brenner and John Mekalanos.

Gary BrennerFounder

John MekalanosFounder

Neil KirbyChief Executive Officer

Susan LuoExecutiveSusan Luo is cofounder of Mulberry Biotherapeutics, a developer of bacteria-mediated immunotherapies for rare tumors, and has served as a private investor and advisor to other healthcare organizations.

Board

Philip R. ReillyBoard director

Reported raises · per SEC filings

Form D private placements

$2.1M disclosed across 1 round · 2021

▶$2.1MraisedApr 2021 · 17 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Neil KirbyExecutive Officer
Susan LuoExecutive Officer
Philip R. ReillyDirector

Offering amount: $2.8M
Amount sold: $2.1M
First sale: Apr 2021
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Mulberry Biotherapeutics went on to found or lead other companies.

Sven KarlssonAdvisorFounded Stellular Bio +1 Neil KirbyCEO and Board MemberFounded Bridgebio

Related companies · 5

Mission BioCapital Platinum Program Holdings LLCMission BioCapital is a venture capital firm that invests in early-stage life science companies, from therapeutics and drug discovery to biotech tools and diagnostics. The firm provides capital, operational support, and lab infrastructure through its MBC BioLabs co-working spaces to help scientific entrepreneurs launch and scale biotech startups.

Modulate BioModulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.

Orum Therapeutics Venture CapitalOrum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.

Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.

Muna TherapeuticsMuna Therapeutics is a biotechnology company developing therapeutics, with a focus on drug discovery involving medicinal chemistry.

Companies working in the same space as Mulberry Biotherapeutics.

Frequently asked questions

What does Mulberry Biotherapeutics do?: Mulberry Biotherapeutics develops bacteria-mediated immunotherapies using genetically engineered, live-attenuated Salmonella Typhimurium injected directly into tumors to treat rare, slow-growing tumors. Its lead program, MUL001, targets Neurofibromatosis type 2-related schwannomatosis (NF2-SWN), with planned follow-on indications including NF1-associated nerve sheath tumors and meningiomas.
Who founded Mulberry Biotherapeutics?: Mulberry Biotherapeutics was founded by Gary Brenner, John Mekalanos in 2020.
How much funding has Mulberry Biotherapeutics raised?: Mulberry Biotherapeutics has disclosed $2.1M raised across 1 round.
Where is Mulberry Biotherapeutics headquartered?: Mulberry Biotherapeutics is headquartered in Wellesley, US.